HLS Therapeutics Inc. (HLS.TO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Craig Stuart Millian M.B.A. | CEO & Director | 1.25M | -- | 1968 |
| Mr. John Hanna CPA, CGA, M.B.A. | CFO & Non-Independent Director | 652.55k | -- | 1965 |
| Dr. Jason A. Gross Pharm.D. | Vice President of Scientific Affairs | 394.97k | -- | 1965 |
| Mr. Ryan C. Lennox B.A., J.D. | Senior VP of Legal, HR & Compliance and Corporate Secretary | 501.41k | -- | 1981 |
| Mr. Brian T. Walsh | Chief Commercial Officer | 609.21k | -- | -- |
| Dave Mason | Investor Relations Officer | -- | -- | -- |
| Mr. David Spence | VP & Corporate Controller | -- | -- | 1968 |
HLS Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 92
Description
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Corporate Governance
Upcoming Events
August 6, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
HLS Therapeutics Inc. Earnings Date
Recent Events
June 15, 2023 at 12:00 AM UTC
Dividend Date
April 27, 2023 at 12:00 AM UTC
Ex-Dividend Date